GlassScriptPhysician profile
Alix H Ackerman
NPI 1184246449
$933.29
in general payments reported to CMS, 2019-2025
14 companies · $90.30 in 2025
The $90.30 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $230 · 2023: $149 · 2024: $183 · 2025: $90.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $162.17 | 2021-2024 | Breztri |
| Lilly USA, LLC | $122.12 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.18 | 2021-2022 | |
| Heron Therapeutics, INC. | $90.30 | 2025 | Zynrelef |
| Bayer Healthcare Pharmaceuticals INC. | $89.16 | 2022-2023 | |
| Daiichi Sankyo INC. | $83.28 | 2021-2023 | Injectafer |
| Bioventus LLC | $72.90 | 2024 | Exogen Ultrasound Bone Healing System |
| Amgen INC. | $61.96 | 2021-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $46.86 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $32.16 | 2021-2024 | |
| Glaxosmithkline, LLC. | $29.60 | 2023 | Trelegy Ellipta |
| Eisai INC. | $15.25 | 2024 | |
| Boston Scientific Corporation | $14.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alix Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.